Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

27 juil. 2021 02h00 HE | Source: Artios Pharma, Inc.

Artios Announces $153 Million (£110 Million) Series C Financing Led by Omega Funds and TCG X

Funding propels Artios’ ability to progress beyond synthetic lethality and to continue the exploitation of the full spectrum of oncology vulnerabilities presented by the DNA Damage Response through...
17 juin 2021 11h00 HE | Source: Artios Pharma, Inc.

Artios Pharma Publishes Preclinical Data on The First Selective Small Molecule Polθ Polymerase Inhibitor in Nature Communications

Artios’ small molecule Polθ inhibitor elicits BRCA-gene synthetic lethality and PARP inhibitor synergyGenetic screening reveals biomarkers within the PARP inhibitor resistance setting to enable...
07 avr. 2021 02h00 HE | Source: Artios Pharma, Inc.

Artios Pharma Announces Collaboration with Novartis to Create Next Generation DDR Cancer Therapies

Novartis to leverage Artios’ discovery platform to identify DDR targets for use with Novartis’ proprietary radioligand therapies.Artios to receive US$20 million up-front payment in addition to near...